← All trials
NCT04128891
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2020
- Primary completion
- Feb 1, 2022
- Completion date
- Feb 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Flinders UniversityLead sponsor
- University of AdelaideOverall official - principal investigator
- Flinders UniversityReponsible party - principal investigator
- University of SydneyOverall official - principal investigator
- Flinders UniversityOverall official - principal investigator
- The Alfred HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.